ESTRO 2020 Abstract Book

ESTRO 2020 ONLINE CONGRESS 28 November - 1 December 2020 Table of contents

SATURDAY 28 NOVEMBER 2020

Teaching Lecture The ultimate truth on how to get your paper published in an ESTRO journal ..................................................... (Abs. 1-4) Differential biological effects of photon and particle irradiation: experimental highlights and clinical impact... (Abs. 5) Fractionation in prostate cancer radiotherapy . ......................................................................................................... (Abs. 6) Which organs should be spared to achieve optimal dose distribution in thoracic tumours? ............................... (Abs. 7) Do’s and don’ts in automated treatment planning – optimising conditions and expectations ............................. (Abs. 8) IAEA guide on Radiation Protection and Safety in Medical Uses of Ionising Radiation .......................................... (Abs. 9) The evolution of RTT leadership in radiation oncology ........................................................................................... (Abs. 10) Symposium Management of complex skin targets-what is the optimal radiation technique? . ......................................... (Abs. 11-14) Cutting-edge genomics in radiation oncology .................................................................................................... (Abs. 15-18) Debate This house believes that Elective nodal radiotherapy should be performed for high risk prostate cancer .....(Abs. 19-22) This house believes that upfront radiotherapy is mandatory in patients with brain mets even in the era of immunotherapy ...................................................................................................................... (Abs. 23-26) Symposium Where automation can or cannot help the medical physicist .......................................................................... (Abs. 27-29) Joint Symposium ESTRO-AAPM: The future of Medical Physics in Radiation Oncology ............................................................... (Abs. 30-34) Symposium RTT leadership in radiation oncology................................................................................................................... (Abs. 35-37) Poster Highlights Poster highlights 1 CL: Head & Neck ................................................................................................................... (Abs. 38-44) Poster highlights 2 PH: Dosimetry and detectors .............................................................................................. (Abs. 45-50) Poster discussion CL: Head and neck 1 .............................................................................................................................................. (Abs. 51-55) CL: Prostate 1 ......................................................................................................................................................... (Abs. 56-61) Radiobiology .......................................................................................................................................................... (Abs. 62-67) RTT 1 ....................................................................................................................................................................... (Abs. 68-73) Proffered Papers Proffered papers 1: HSR HERO . ........................................................................................................................... (Abs. 74-79) Proffered papers 2: Interactions between radiation and the immune response ........................................... (Abs. 80-85) Proffered papers 3: Sarcoma ............................................................................................................................... (Abs. 86-90) Proffered papers 4: CNS ....................................................................................................................................... (Abs. 91-95) Proffered papers 5: Analysis for toxicity and outcome ................................................................................... (Abs. 96-101) Proffered papers 6: Novel treatment planning strategies ............................................................................ (Abs. 102-107) Proffered papers 7: Evaluating and predicting toxicity in RT ........................................................................ (Abs. 108-113) Poster Highlights Poster highlights 3 CL : Prostate ...................................................................................................................... (Abs. 114-120) Poster highlights 4 PH: Intrafractional motion ............................................................................................... (Abs. 121-127)